Clinical trial DT-9081-CLI-001
A phase 1a, multicenter, open-label, dose-escalation study to determine a recommended clinical dose (RCD) of DT-9081, followed by an expansion study of DT-9081 at RCD in participants with advanced/metastatic solid tumours (DT-9081-CLI-001)
| Organ | Multiple |
|---|---|
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Domain therapeutics |
| EudraCT Identifier | 2022-000092-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05582850 |
| Last update |